The U.K. cost-effectiveness standard for drugs will increase by 25% in exchange for zero tariffs on the country’s ...

Americans largely trust their doctors but are skeptical of payers, drugmakers and hospital leadership — a divide fueled by ...

As we approach 2025, healthcare marketing stands at a pivotal crossroads, one where traditional healthcare delivery models will increasingly intersect with technological innovation and evolving ...

SmarterDx closed a $50 million Series B funding round on Tuesday, bringing the startup’s total funding to date to $71 million. The New York-based company is a healthcare AI startup that provides ...

Pancreatic cancer continues to be one of the most difficult-to-treat cancers. An Ipsen drug is now approved as a first-line therapy, moving it up in the treatment hierarchy for this type of cancer.

About 22 million Americans would face sharply higher healthcare costs if enhanced ACA tax credits expire at the end of the ...

A Travere Therapeutics drug that won speedy approval early this year for a rare autoimmune kidney disorder has failed to meet the key goal of its confirmatory study. Still, the biotech points to data ...

Light chain amyloidosis is not cancer, but cancer drugs are this rare disease’s standard of care. The patient need for new treatment options has sparked R&D efforts at biotech and big pharmaceutical ...

From hospice centers to emergency rooms, frontline healthcare workers across the country have been striking this month to protest what they say are unsafe patient care conditions and poor bargaining ...

A recent IT issue at cybersecurity software company CrowdStrike resulted in a tech outage that has left companies all over the globe reeling — from banks to airlines to of course, healthcare providers ...

Capricor Therapeutics’ cell therapy for Duchenne muscular dystrophy has come up short at the FDA, with the regulator rejecting the biotech’s application seeking regulatory approval for what the ...

Johnson & Johnson currently boasts one of the largest lineups of multiple myeloma products. Since its first FDA approval of a drug for this type of blood cancer a decade ago, the pharmaceutical giant ...